Literature DB >> 12675997

Gonadotrophin regimens and oocyte quality in women with polycystic ovaries.

Stephen Franks1, Ruth Roberts, Kate Hardy.   

Abstract

The systemic endocrine environment during the later stages of follicle development has a crucial role in co-ordinating follicular and oocyte maturation before ovulation. Polycystic ovary syndrome (PCOS) is associated with abnormal circulating hormones, abnormal peri-follicular vascularity and significant abnormalities of granulosa cell function. After induction of ovulation, fertilization rates in vivo in women with PCOS are normal, but there is an increased risk of early pregnancy loss, particularly in obese patients. After in-vitro maturation of oocytes or following ovulation induction for IVF, oocyte and embryo quality in vitro are not obviously impaired in PCOS. In some reports however, specific endocrine abnormalities, such as hyperinsulinaemia/insulin resistance, have been noted to be associated with reduced fertilization rates and abnormal early embryonic development.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12675997     DOI: 10.1016/s1472-6483(10)61708-7

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  13 in total

1.  Vacuolated oocytes: fertilization and embryonic arrest following intra-cytoplasmic sperm injection in a patient exhibiting persistent oocyte macro vacuolization--case report.

Authors:  Sarah Wallbutton; Jason Kasraie
Journal:  J Assist Reprod Genet       Date:  2010-03-02       Impact factor: 3.412

Review 2.  Ovarian and Extra-Ovarian Mediators in the Development of Polycystic Ovary Syndrome.

Authors:  Muraly Puttabyatappa; Vasantha Padmanabhan
Journal:  J Mol Endocrinol       Date:  2018-10-16       Impact factor: 5.098

3.  Single-cell expression analysis of BMP15 and GDF9 in mature oocytes and BMPR2 in cumulus cells of women with polycystic ovary syndrome undergoing controlled ovarian hyperstimulation.

Authors:  Luciana Ochuiuto Teixeira de Resende; Alessandra Aparecida Vireque; Laura Ferreira Santana; Daniel Antunes Moreno; Ana Carolina Japur de Sá Rosa e Silva; Rui Alberto Ferriani; Carlos Alberto Scrideli; Rosana Maria Reis
Journal:  J Assist Reprod Genet       Date:  2012-07-24       Impact factor: 3.412

Review 4.  Infertility in polycystic ovary syndrome: focus on low-dose gonadotropin treatment.

Authors:  Anwen Gorry; Davinia M White; Stephen Franks
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

Review 5.  Developmental origin of reproductive and metabolic dysfunctions: androgenic versus estrogenic reprogramming.

Authors:  Vasantha Padmanabhan; Almudena Veiga-Lopez
Journal:  Semin Reprod Med       Date:  2011-06-27       Impact factor: 1.303

Review 6.  Is ovulation induction still a therapeutic problem in patients with polycystic ovary syndrome?

Authors:  S Palomba; F Orio; T Russo; A Falbo; T Cascella; A Colao; G Lombardi; F Zullo
Journal:  J Endocrinol Invest       Date:  2004-09       Impact factor: 4.256

7.  Long-term Hyperandrogenemia and/or Western-style Diet in Rhesus Macaque Females Impairs Preimplantation Embryogenesis.

Authors:  Sweta Ravisankar; Melinda J Murphy; Nash Redmayne-Titley; Brett Davis; Fangzhou Luo; Diana Takahashi; Jon D Hennebold; Shawn L Chavez
Journal:  Endocrinology       Date:  2022-04-01       Impact factor: 4.736

Review 8.  Animal models of the polycystic ovary syndrome phenotype.

Authors:  Vasantha Padmanabhan; Almudena Veiga-Lopez
Journal:  Steroids       Date:  2013-05-20       Impact factor: 2.668

Review 9.  Sheep models of polycystic ovary syndrome phenotype.

Authors:  Vasantha Padmanabhan; Almudena Veiga-Lopez
Journal:  Mol Cell Endocrinol       Date:  2012-10-16       Impact factor: 4.102

Review 10.  The Potential Relationship Between Different Human Female Reproductive Disorders and Sperm Quality in Female Genital Tract.

Authors:  Forough Mahdavinezhad; Roghaye Gharaei; Ahmad Reza Farmani; Farideh Hashemi; Mahsa Kouhestani; Fardin Amidi
Journal:  Reprod Sci       Date:  2021-04-14       Impact factor: 3.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.